You are here

  • Home
  • Archive
  • Volume 10, Issue 9
  • COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

 

Online download statistics by month:

Online download statistics by month: September 2022 to March 2026

AbstractFullPdf
Sep 2022548554118
Oct 202228929587
Nov 202216616894
Dec 202214014158
Jan 202325225382
Feb 202315515771
Mar 202313213239
Apr 2023919352
May 202311511577
Jun 202312312365
Jul 2023969659
Aug 202311211274
Sep 2023848449
Oct 2023686828
Nov 2023777735
Dec 2023595942
Jan 202411311479
Feb 2024878966
Mar 2024777783
Apr 2024737462
May 2024838453
Jun 2024939362
Jul 202411211347
Aug 2024464735
Sep 2024575749
Oct 2024626248
Nov 2024939473
Dec 202416617187
Jan 202512212265
Feb 202510410649
Mar 202516216476
Apr 202514214269
May 202510310361
Jun 202511211340
Jul 2025110
Feb 2026110
Total431643542134